Drug
AV 299 Gefitinib
AV 299 Gefitinib: highest development phase Phase 1/2, developed by Aveo Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Aveo Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| AV-299 + gefitinib NCT01039948 | Phase 1/2 | Carcinoma, Non-Small Cell-Lung |
Latest
No recent events.
Follow AV 299 Gefitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.